uniQure (NASDAQ:QURE) Given New $68.00 Price Target at Leerink Partners

Key Points

• Investment analysts at Leerink Partners raised uniQure's price target from $48.00 to $68.00, indicating a potential upside of 48.02% from the stock's previous close.
• uniQure's stock has experienced a significant increase, trading at $45.94 with a trading volume of over 60 million shares, pointing to notable investor interest.
• Despite the positive outlook from analysts, uniQure reported a negative earnings per share (EPS) of ($0.69), although it surpassed consensus estimates by $0.20.

uniQure (NASDAQ:QURE - Get Free Report) had its price objective boosted by investment analysts at Leerink Partners from $48.00 to $68.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Leerink Partners' price objective suggests a potential upside of 48.02% from the stock's previous close.

Several other equities research analysts have also recently weighed in on QURE. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research note on Wednesday, July 30th. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Mizuho raised uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 target price on the stock in a research note on Thursday, August 14th. Chardan Capital reaffirmed a "buy" rating and set a $35.00 target price on shares of uniQure in a research note on Monday, September 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of uniQure in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $39.64.

uniQure Price Performance

Shares of QURE stock traded up $32.28 during trading hours on Wednesday, hitting $45.94. The stock had a trading volume of 60,552,116 shares, compared to its average volume of 1,680,661. uniQure has a one year low of $4.45 and a one year high of $51.21. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The stock's 50-day moving average price is $15.24 and its two-hundred day moving average price is $14.09. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -11.59 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The firm had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. Equities analysts forecast that uniQure will post -3.75 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Main Management ETF Advisors LLC lifted its holdings in uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company's stock worth $786,000 after buying an additional 912 shares during the period. Tower Research Capital LLC TRC lifted its holdings in uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock worth $99,000 after buying an additional 5,538 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in uniQure during the second quarter worth $117,000. Birchview Capital LP lifted its holdings in shares of uniQure by 11.3% during the 2nd quarter. Birchview Capital LP now owns 98,697 shares of the biotechnology company's stock valued at $1,376,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of uniQure by 3.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company's stock valued at $2,968,000 after purchasing an additional 10,019 shares during the last quarter. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.